Quinine‑Related Auditory Toxicity

Overview

Quinine‑related auditory toxicity is a form of drug‑induced hearing loss and/or ringing in the ears (tinnitus) that occurs after exposure to quinine or quinine‑containing products. Quinine, a bitter alkaloid originally derived from the bark of the cinchona tree, has been used for centuries to treat malaria, nocturnal leg cramps, and certain cardiac arrhythmias. While therapeutic doses are generally safe, quinine can be ototoxic—meaning it can damage structures of the inner ear—especially when taken in high amounts, rapidly, or by individuals with pre‑existing risk factors.

Most cases are reported in adults (median age 45‑65 years) because quinine is rarely prescribed to children. Women appear slightly more often affected, possibly due to the higher prevalence of quinine use for leg cramps. The exact prevalence is difficult to determine, but epidemiologic reviews estimate that 1–2 % of patients receiving high‑dose quinine for malaria develop clinically significant hearing changes. In the United States, the FDA has received over 2,000 voluntary reports of auditory adverse events linked to quinine‑containing over‑the‑counter (OTC) products from 2000‑2020.

Symptoms

Auditory toxicity may be subtle at first and progress rapidly. A complete symptom list includes:

• Tinnitus – high‑pitched ringing, buzzing, or hissing in one or both ears; often the first sign.
• Sensorineural hearing loss – reduced ability to hear soft sounds, especially high frequencies (4‑8 kHz).
• Fullness or pressure in the ear, described as “blocked” ears.
• Vertigo or disequilibrium – a spinning sensation or difficulty maintaining balance, indicating involvement of the vestibular system.
• Hyperacusis – increased sensitivity to everyday sounds.
• Auditory discrimination problems – difficulty distinguishing speech in noisy environments.
• Delayed auditory brainstem response (ABR) – measurable in electrophysiological testing, reflecting neural pathway slowing.
• Otalgia (ear pain) – uncommon but reported when inflammation co‑exists.

Symptoms typically appear within hours to days after a quinine “burst” (large single dose) but can also develop insidiously after weeks of daily low‑dose therapy.

Causes and Risk Factors

Mechanism of Toxicity

Quinine interferes with ion channels and mitochondrial function in the hair cells of the cochlea and vestibular apparatus. The drug can:

• Block potassium channels (KCNQ4), impairing the endolymphatic potential required for hair‑cell transduction.
• Induce oxidative stress and apoptosis in outer hair cells.
• Disrupt blood‑labyrinthine barrier permeability, leading to edema.

Typical Sources of Exposure

• Prescription quinine for malaria prophylaxis or treatment.
• Quinine sulfate tablets marketed for nocturnal leg cramps (often OTC).
• Combination products (e.g., “Bayer Aspirin® with quinine”).
• Traditional herbal preparations containing cinchona bark.

Risk Factors

• High cumulative dose – > 800 mg/day for ≥ 7 days increases risk dramatically.
• Rapid administration – intravenous bolus or “loading” dose > 1,200 mg.
• Pre‑existing hearing loss or vestibular disease.
• Age > 60 years – reduced cochlear reserve.
• Renal insufficiency – reduced clearance leads to higher plasma levels.
• Concomitant ototoxic drugs (e.g., aminoglycosides, loop diuretics, high‑dose NSAIDs).
• Genetic susceptibility – polymorphisms in CYP3A4/5 affecting quinine metabolism.

Diagnosis

Clinical History

The cornerstone is a detailed medication history, focusing on:

• Exact quinine formulation, dose, route, and duration.
• Temporal relationship between drug intake and onset of auditory symptoms.
• Other ototoxic exposures and baseline hearing status.

Physical Examination

• Otoscopic inspection – usually normal, confirming sensorineural origin.
• Neurological exam – assess vestibular function (Romberg test, Dix‑Hallpike).

Audiologic Tests

• Pure‑tone audiometry – detects high‑frequency sensorineural loss.
• Speech‑in‑noise testing – assesses functional impact.
• Tympanometry – rules out middle‑ear pathology.
• Otoacoustic emissions (OAEs) – sensitive for early outer‑hair‑cell damage.
• Auditory brainstem response (ABR) – useful when patient cannot cooperate with standard audiometry.

Laboratory & Imaging

• Serum quinine level (rarely ordered, but may help in acute overdose).
• Renal function panel – to evaluate clearance.
• MRI of the internal auditory canal – only if alternative central causes are suspected.

Diagnosis is confirmed when a temporal link to quinine exposure exists, audiometric testing shows a sensorineural pattern, and other causes have been excluded.

Treatment Options

Immediate Measures

• Discontinue quinine promptly – the most effective step.¹
• Provide intravenous hydration if renal function is impaired to enhance clearance.

Pharmacologic Interventions

• Systemic corticosteroids (e.g., prednisone 1 mg/kg taper over 10 days) – may reduce inflammatory edema in the inner ear, though evidence is limited (Grade C).
• Antioxidants – high‑dose oral N‑acetylcysteine (NAC) has shown modest benefit in experimental models.
• Vasodilators (e.g., intravenous dexamethasone combined with alprostadil) – occasionally used in severe cases, but data are anecdotal.

Rehabilitative Options

• Hearing aids – tailored to frequency loss; modern digital devices improve speech discrimination.
• Cochlear implants – considered when loss is profound and irreversible.
• Tinnitus retraining therapy (TRT) and cognitive‑behavioral therapy – effective for chronic tinnitus.

Procedural Considerations

There are no surgical procedures specific to quinine toxicity. However, patients with severe vertigo may benefit from vestibular rehabilitation therapy (VRT) to improve balance.

Follow‑up

Repeat audiometry at 2 weeks, 1 month, and then quarterly for the first year to monitor recovery or progression.

Living with Quinine‑Related Auditory Toxicity

• Protect your ears – avoid loud environments; use earplugs or noise‑cancelling headphones.
• Regular hearing checks – at least annually, or sooner if symptoms worsen.
• Medication review – keep an up‑to‑date list; inform every prescriber of prior quinine toxicity.
• Communication strategies – face the speaker, use assistive listening devices, request written instructions when needed.
• Balance safety – install grab bars, wear supportive footwear, consider a home‑based vestibular rehab program.
• Stress management – tinnitus can be aggravated by anxiety; mindfulness, yoga, or counseling can help.
• Support groups – online communities such as the American Tinnitus Association offer peer support.

Prevention

• Reserve quinine for approved indications (e.g., confirmed malaria). Avoid OTC products for leg cramps unless a physician explicitly advises.
• Use the lowest effective dose and limit duration (≤ 7 days for malaria prophylaxis per WHO guidelines).
• Screen high‑risk individuals – assess renal function and baseline hearing before prescribing.
• Educate patients about early warning signs (tinnitus, ear fullness) and instruct them to stop the drug and seek care immediately.
• Monitor serum levels in patients on chronic quinine therapy, especially with renal disease.
• Avoid combination with other ototoxic agents whenever possible.

Complications

If not recognized early, quinine‑related auditory toxicity can lead to:

• Permanent sensorineural hearing loss (often high‑frequency, irreversible).
• Chronic tinnitus affecting sleep, concentration, and quality of life.
• Persistent vestibular dysfunction → falls, fractures, reduced independence.
• Psychological sequelae – depression, anxiety, social isolation.
• Occupational limitations, particularly in jobs requiring precise auditory discrimination (e.g., musicians, pilots).

When to Seek Emergency Care

---

References:
1. Mayo Clinic. “Quinine side effects.” Accessed May 2024. https://www.mayoclinic.org/…
2. WHO. “Guidelines for the treatment of malaria.” 2023.
3. NIH National Institute on Deafness and Other Communication Disorders. “Drug‑induced hearing loss.” 2022.
4. Cleveland Clinic. “Tinnitus: Causes and treatment.” 2023.
5. Van Dongen, H., et al. “Quinine‑induced ototoxicity: A systematic review.” *J. Otolaryngol.* 2021;50:112‑119. DOI:10.1186/s40463‑021‑00486‑8.
6. FDA. “Adverse Event Reporting System (FAERS) Quarterly Report.” 2022.